title: On biomarkers and pathways in rectal cancer: What's the target?
abstract: In spite of tremendous progresses in surgical and chemo-radiotherapeutic regimens, rectal cancer still suffers from high relapse and mortality rates, and metastatic disease is incurable. Here we assess some of the most recent and validated biomarkers and potential targets studied in rectal cancer, and provide comments to a recent monographic topic covering several aspects of colorectal cancer, published in Current Cancer Drug Targets.
authors.affiliation: Gabriele Zoppoli, Department of Internal Medicine, Istituti di Ricovero e Cura a Carattere Scientifico, Azienda Ospedaliera Universitaria San Martino, Istituto Nazionale per la Ricerca sul Cancro, Istituto Scientifico Tumori, 16137 Genova, Italy.
authors.forename: Gabriele
authors.initials: G
authors.lastname: Zoppoli
authors.forename: Valter
authors.initials: V
authors.lastname: Ferrando
authors.forename: Stefano
authors.initials: S
authors.lastname: Scabini
keywords: Biological markers; Chemotherapy; Colorectal surgery; Rectal cancer; Targeted molecular therapy